RewordedRisk Factors
We are subject to regulation under a variety of U.S. federal and state and non-U.S. laws, regulations and policies, including laws related to environmental, health and safety, sustainability, anti-corruption, export and import compliance, anti-trust anti-trust, money laundering, data privacy, and money laundering artificial intelligence due to our global operations.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, negative or inaccurate postings or comments comments, misinformation, and disinformation across the media landscape, including on social media or networking websites about the Company or our brands could generate adverse publicity that could damage our reputation or the reputation of our brands.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our daily business operations also require us to collect and/or retain sensitive data such as intellectual property, proprietary business information and data related to customers, employees, suppliers and business partners within our networking infrastructure including data from individuals subject to the European Union's General Data Protection Regulation, that is subject to privacy and security laws, regulations and/or customer-imposed controls.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Unfavorable changes and instability in economic conditions, including inflation, monetary policies, recession, changes in tariffs and trade relations amongst international trading partners, geopolitical tensions and increased geopolitical volatility, or other changes in economic conditions, may adversely impact the markets in which we operate.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our sales and operations are subject to a number of risks, including political and economic instability and instability, geopolitical tensions, and increased geopolitical volatility, which could have a material adverse impact on our ability to increase or maintain our international sales and operations.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Political or financial economic instability, geopolitical tensions, tensions and volatility, currency fluctuations, the outbreak of pandemics or other illnesses (such as the COVID-19 pandemic), labor unrest, transport capacity and costs, port security, weather conditions, natural disasters, or other events that could alter or suspend our operations, slow or disrupt port activities, or affect foreign trade are beyond our control and could materially disrupt our supply of raw materials, increase our costs, and/or adversely affect our results of operations.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In light of potential fluctuations, including interest rate increases which may continue, increases, we are exposed to risk resulting from adverse changes in interest rates.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our U.S. and non-U.S. operations are subject to a number of laws and regulations, including food and feed regulations, and environmental, health and safety standards.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Despite rigorous processes, we may not adequately meet all our existing or future disclosure obligations and/or having we may have our disclosures misinterpreted.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
AddedMD&A
In late June 2025, the European Commission announced that it would impose provisional duties between 95.4% and 120.8% on imports into the European Union of choline chloride originating in the People’s Republic of China, effective July 1, 2025. The investigation was initiated by the European Commission in late October 2024, following a complaint lodged by Balchem Italia Srl and another complainant. On December 19, 2025, the European Commission published their final decision to set definitive duties between 90.0% and 115.9%. Further, the European Commission set rules to make it clear that the country of origin of choline chloride, regardless of form, will be the country where the chemical reaction between trimethylamine hydrochloride and ethylene oxide takes place.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
AddedMD&A
manufacturer to add capacity amounted to $323 and $24,164 for the years ended December 31, 2025 and 2024, respectively, net of cash acquired.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RemovedMD&A
On August 30, 2022, we completed the acquisition of Bergstrom, a leading science-based manufacturer of MSM, based in Vancouver, Washington, and on June 21, 2022, we completed the acquisition of Kappa, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. Details related to both acquisitions are disclosed in Note 2, Significant Acquisitions, and the "Acquisitions" section in Item 1. Business.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
•Sales relating to Other decreased from the prior year primarily due to lower average selling prices.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RemovedMD&A
•The decrease in Other and unallocated was primarily driven by the aforementioned lower sales, partially offset by lower unallocated corporate expenses.
Read it in 10-K Feb 21, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in operating expenses was primarily due to the impact of favorable adjustments to transaction costs in the prior year of $11,300, an increase in compensation-related expenses of $9,074, $8,327 and higher professional services of $1,950, and the impact of a gain on the sale of fixed assets of $1,338 in the prior year, $3,856, partially offset by lower amortization expense of $8,867 $2,376 and a decrease in restructuring-related impairment charges agent and broker commissions of $7,243. $1,132.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
The deferred compensation liability related rabbi trust assets was $11,470 $12,798 as of December 31, 2024, 2025, of which $11,449 $12,773 was included in "Other long-term obligations" non-current assets" and $21 $25 was included in "Accrued compensation and other benefits" "Other current assets" on our condensed the Company's consolidated balance sheets.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Business Segment Net Sales 2025 2024 2023 2022 Human Nutrition and Health $ 659,387 $ 600,258 $ 550,751 $ 527,131 Animal Nutrition and Health 230,852 214,710 238,326 262,297 Specialty Products 140,976 132,749 125,965 131,438 Other and Unallocated (1) 5,946 5,967 7,397 21,492 Total $ 1,037,161 $ 953,684 $ 922,439 $ 942,358 Business Segment Earnings From Operations 2025 2024 2023 2022 Human Nutrition and Health $ 153,906 $ 135,957 $ 102,419 $ 82,125 Animal Nutrition and Health 18,687 14,013 27,576 36,056 Specialty Products 42,901 39,906 34,579 32,789 Other and Unallocated (1) (6,168) (6,967) (5,381) (5,784) Total $ 209,326 $ 182,909 $ 159,193 $ 145,186 (1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
(i) Transaction and integration costs, ERP implementation costs, costs of $1,242, $1,484 and unallocated legal fees totaling $1,484, $1,617 and $3,581 for years ended December 31, 2024, 2023 2025, 2024 and 2022, 2023, respectively, and (ii) Unallocated amortization expense of $0, $312, $0, and $2,951 $312 for years ended December 31, 2025, 2024, and 2023, and 2022, respectively, related to an intangible asset in connection with a company-wide ERP system implementation.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Gross margin dollars increased for 2024 2025 compared to 2023 2024 due to higher sales, sales and a favorable mix and a decrease in cost of goods sold of $2,905. mix, partially offset by certain higher manufacturing input costs.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Total sales for this segment decreased increased by 9.9%, 7.5%, with average selling prices contributing -6.1% and 5.6%, volume and mix contributing -3.8%. 1.0%, and the change in foreign currency exchange rates contributing 0.9%.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in the effective tax rate was primarily due to an increase a decrease in certain state and foreign taxes. taxes partially offset by lower tax benefits from stock-based compensation.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
In 2024, 2025, we borrowed $26,000 $88,000 to fund share repurchases and the payment of the 2023 dividend 2024 dividend, and made total loan repayments of $145,569, $114,000, resulting in $360,000 $386,000 available under the 2022 Credit Agreement (see Note 8, 7, Revolving Loan) as of December 31, 2024. 2025.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Total sales for this segment grew 9.0%, 9.9%, with volume and mix contributing 6.6% and 6.6%, average selling prices contributing 2.4%. 2.8%, and the change in foreign currency exchange rates contributing 0.4%.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Cash and cash equivalents decreased increased to $74,570 at December 31, 2025 from $49,515 at December 31, 2024 from $64,447 at December 31, 2023. 2024.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
Total sales for this segment increased by 5.4%, 6.2%, with average selling prices contributing 3.9% 4.0%, the change in foreign currency exchange rates contributing 1.3%, and volume and mix contributing 1.4%. 0.9%.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in gross margin was primarily due to driven by the aforementioned higher sales and certain lower manufacturing input costs. sales.
Read it in 10-K Feb 20, 2026 at sec.govopen_in_new